Skip to main content
Journal ArticleOPEN ACCESS

Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa

Clinical Infectious Diseases (2005) 41(5) 754-757
DOI: 10.1086/432583
186Citations
Citations of this article
88Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Twenty-one patients with multidrug-resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa pneumonia were treated with nebulized polymyxin E (colistin). Overall clinical and microbiological response rates were 57.1% and 85.7%, respectively. Nebulized colistin may be reasonably efficacious and safe for treatment of MDR pneumonia. Its role in therapy warrants further investigation in comparative studies. © 2005 by the Infectious Diseases Society of America. All rights reserved.

Cite

CITATION STYLE

APA

Kwa, A. L. H., Loh, C. S., Low, J. G. H., Kurup, A., & Tam, V. H. (2005). Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clinical Infectious Diseases, 41(5), 754–757. https://doi.org/10.1086/432583

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free